Answers are grounded in this paper and cite their sources.
A review of the use of microdoses and isotopic microtracers for clinical intravenous pharmacokinetic (i.v. PK) data provision is presented. The extent of application of the varied approaches available and the relative merits of each are highlighted with the aim of assisting practitioners in making informed decisions on the most scientifically appropriate design to adopt for any given new drug in development. It is envisaged that significant efficiencies will be realized as i.v. PK data in humans becomes more routinely available for suitable assets in early development, than has been the case prior to the last decade.
No takes yet. Share an insight, caveat, or question.
Young et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: